Human variability and noncancer risk assessment - An analysis of the default uncertainty factor

被引:189
作者
Renwick, AG
Lazarus, NR
机构
[1] Univ Southampton, Clin Pharmacol Grp, Southampton SO16 7PX, Hants, England
[2] Open Univ, SE Reg, E Grinstead AH19 1ES, W Sussex, England
关键词
uncertainty factor; human variability; toxicokinetics; toxicodynamics; interindividual differences;
D O I
10.1006/rtph.1997.1195
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A 10-fold uncertainty factor is used for noncancer risk assessments to allow for possible interindividual differences between humans in the fate of the chemical in the body (kinetics) and target organ sensitivity (dynamics). Analysis of a database on the variability in each of these aspects is consistent with an even subdivision of the 10-fold factor into 10(0.5) (3.16) for kinetics and 10(0.5) (3.16) for dynamics. Analysis of the number of subjects in a normally and log-normally distributed population which would not be covered by factors of 3.16 supports this subdivision and also the use of a 10-fold factor to allow for both aspects. Analysis of kinetic data for subgroups of the population indicates that the standard default value of 3.16 for kinetics will not be adequate for all routes of elimination and all groups of the population. A scheme is proposed which would allow the selection of appropriate default uncertainty factors based on knowledge of the biological fate and effects of the chemical under review. (C) 1998 Academic Press.
引用
收藏
页码:3 / 20
页数:18
相关论文
共 142 条
[11]   PHARMACOKINETICS OF PHENYTOIN IN CHILDREN [J].
BLAIN, PG ;
MUCKLOW, JC ;
BACON, CJ ;
RAWLINS, MD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (05) :659-661
[12]   A POPULATION STUDY OF THE PHARMACOKINETICS OF FELODIPINE [J].
BLYCHERT, E ;
EDGAR, B ;
ELMFELDT, D ;
HEDNER, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (01) :15-24
[13]   PLASMA-CONCENTRATION - EFFECT RELATIONSHIPS FOR FELODIPINE - A METAANALYSIS [J].
BLYCHERT, E ;
EDGAR, B ;
ELMFELDT, D ;
HEDNER, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) :80-89
[14]   QUANTIFICATION OF THEOPHYLLINE-INDUCED EOSINOPENIA AND HYPOKALEMIA IN HEALTHY-VOLUNTEERS [J].
BRAAT, MCP ;
JONKERS, RE ;
BEL, EH ;
VANBOXTEL, CJ .
CLINICAL PHARMACOKINETICS, 1992, 22 (03) :231-237
[15]   QUANTIFICATION OF METOPROLOL BETA-2-ADRENOCEPTOR ANTAGONISM IN ASTHMATIC-PATIENTS BY PHARMACOKINETIC PHARMACODYNAMIC MODELING [J].
BRAAT, MCP ;
JONKERS, RE ;
VANBOXTEL, CJ .
PULMONARY PHARMACOLOGY, 1992, 5 (01) :31-38
[16]   THE METABOLISM OF CYCLAMATE TO CYCLOHEXYLAMINE AND ITS CARDIOVASCULAR CONSEQUENCES IN HUMAN VOLUNTEERS [J].
BUSS, NE ;
RENWICK, AG ;
DONALDSON, KM ;
GEORGE, CF .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1992, 115 (02) :199-210
[17]   THE TERATOGENIC METABOLITES OF VITAMIN-A IN WOMEN FOLLOWING SUPPLEMENTS AND LIVER [J].
BUSS, NE ;
TEMBE, EA ;
PRENDERGAST, BD ;
RENWICK, AG ;
GEORGE, CF .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1994, 13 (01) :33-43
[18]  
CADORNIGA R, 1990, INT J CLIN PHARM TH, V28, P435
[19]   UNCERTAINTY FACTORS AND INTERINDIVIDUAL VARIATION [J].
CALABRESE, EJ .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1985, 5 (02) :190-196
[20]   DOES THE ANIMAL-TO-HUMAN UNCERTAINTY FACTOR INCORPORATE INTERSPECIES DIFFERENCES IN SURFACE-AREA [J].
CALABRESE, EJ ;
BECK, BD ;
CHAPPELL, WR .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1992, 15 (02) :172-179